Physician profile
Sam Awan
NPI 1013322858
$586,252.97
in general payments reported to CMS, 2019-2025
41 companies · $241K in 2025
The $241K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,917 · 2020: $1,224 · 2021: $22K · 2022: $103K · 2023: $96K · 2024: $117K · 2025: $241K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $342K · Consulting Fee: $56K · Travel and Lodging: $40K · Food and Beverage: $17K · Education: $98.70 · Honoraria: $30.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $341,825.00 |
| Consulting Fee | $55,701.50 |
| Travel and Lodging | $39,970.75 |
| Food and Beverage | $16,670.08 |
| Education | $98.70 |
| Honoraria | $30.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $390,065.18 | 2019-2025 | Ebglyss, Olumiant, Taltz |
| Galderma Laboratories, L.P. | $130,772.61 | 2019-2025 | Nemluvio, Aklief |
| Eli Lilly and Company | $12,256.63 | 2024-2025 | Olumiant |
| Ucb, INC. | $9,600.53 | 2020-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $7,802.97 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Abbvie INC. | $7,449.61 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Arcutis Biotherapeutics, INC. | $5,368.20 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $3,865.53 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $3,452.84 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $3,380.84 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $2,905.92 | 2019-2025 | |
| Organon LLC | $1,647.92 | 2025 | Vtama |
| Epi Health, LLC | $1,538.73 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $1,336.42 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $876.20 | 2020-2025 | Otezla, Otezla |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Awan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.